The most recent:
Pfizer has submitted to Well being Canada its preliminary information on the effectiveness of its COVID-19 vaccine in kids ages 5 to 11, the division confirmed Saturday.
The corporate has been testing a decrease dose of the photographs in kids.
On Sept. 20, the pharmaceutical large said the first results of its pivotal study point out the vaccine was “secure, well-tolerated and confirmed strong neutralizing antibody responses” in that age group. Pfizer stated it will be submitting its information to regulatory businesses world wide as quickly as potential.
A pivotal trial is normally a Section III research, which presents the info that Well being Canada makes use of to determine whether or not or to not approve a drug.
In an e mail to CBC Information, Well being Canada stated Pfizer submitted its preliminary trial information on Friday afternoon, sooner than anticipated, and is predicted file a proper submission on pediatric photographs in mid-October.
There are presently no vaccines licensed for kids beneath 12 years outdated in Canada. These 12 and older can get both a Pfizer or Moderna vaccine.
What’s occurring throughout Canada
What’s occurring world wide
As of Saturday, greater than 234.3 million circumstances of COVID-19 had been reported worldwide, in keeping with Johns Hopkins College’s coronavirus-tracking software. The reported international demise toll stood at greater than 4.7 million.
In Europe, greater than 5,000 folks protested Saturday in Romania’s capital of Bucharest to reject upcoming measures utilized by authorities to fight an alarming surge infections.
In Asia, U.Okay. nationals visiting India this month should endure obligatory quarantine even when they’re absolutely vaccinated in retaliation for U.Okay. curbs on Indian residents, a senior authorities supply in New Delhi informed Reuters.
Within the Americas, the U.S. demise toll from COVID-19 has eclipsed 700,000, with 100,000 folks dying previously three months when vaccines had been out there to any American over age 12.
In Africa, Nigeria obtained approval on for $400 million US in World Financial institution financing to acquire and deploy COVID-19 vaccinations, the Financial institution stated.